Quick answer: Perimenopause is the transition into menopause — the years when the ovaries wind down and hormone levels become erratic rather than steadily low. Clinically it begins when cycle length turns persistently variable, and it ends 12 months after the final menstrual period.
That last clause is the part most consumer pages skip, and it is not a technicality: it changes when perimenopause is over, and how long you need contraception. What follows is built on the staging system specialists actually use, with two thresholds you can check against your own calendar.
What perimenopause actually is
Perimenopause is the transitional phase leading up to menopause, during which ovarian function declines and the hormones that drive the menstrual cycle stop behaving predictably. It is defined by what your cycles are doing, not by how you feel.
It does not end at your last period. Under the Stages of Reproductive Aging Workshop +10 criteria — STRAW+10, the reference framework for staging reproductive aging — perimenopause "begins at Stage –2 and ends 12 months after the FMP," the final menstrual period (Harlow et al., 2012). So the entire first postmenopausal year sits inside perimenopause. It is common to see the transition described as ending when the bleeding stops; under STRAW+10 it doesn't.
The second thing worth straightening out is the word menopause itself. Menopause is not a phase — it is a single point in time, the final menstrual period, and it can only be identified in hindsight. As the National Institute on Aging puts it, you will only know you have reached it once you have gone a full year with no period or spotting (NIA). Everything before that point is perimenopause; everything after the 12-month mark is postmenopause. These get muddled constantly, which is why premenopause, perimenopause, menopause and postmenopause are worth setting out side by side on a page of their own.
And the mechanism underneath it all: hormone levels do not glide smoothly downward across these years. They swing. STRAW+10 describes the early transition as having "elevated but variable" follicle-stimulating hormone, and the late transition as involving "extreme fluctuations in hormonal levels" (Harlow et al., 2012). Erratic, not linear. Hold onto that, because it explains most of what follows — including why a single blood test is close to useless here.
The stages, and how to tell where you are
There are two numbers you can check yourself, both taken straight from STRAW+10: a persistent difference of 7 days or more between the lengths of consecutive cycles marks the start of the early menopausal transition, and a stretch of 60 days or more with no period marks the late transition (Harlow et al., 2012).
"Persistent" has a definition too: STRAW+10 defines it as recurrence within 10 cycles of the first variable-length cycle. One odd month is not a stage change; the same swing recurring within the next ten cycles is.
| Stage | Name | What's happening to your cycle |
|---|---|---|
| −3a | Late reproductive | Cycles still regular, but subtly changed — specifically, shorter than they used to be |
| −2 | Early menopausal transition | A persistent difference of 7 days or more between the lengths of consecutive cycles |
| −1 | Late menopausal transition | 60 days or more with no period. Estimated to last, on average, 1 to 3 years |
| 0 | Final menstrual period | A single point in time, only identifiable 12 months later |
| +1a | Early postmenopause | The 12 months after the final period — still part of perimenopause |
Criteria from STRAW+10 (Harlow et al., 2012). The full research version also uses anti-Müllerian hormone and antral follicle counts — neither of which you can check at home, nor need to place yourself roughly on this line.
The practical upshot: a paper calendar beats a lab panel here. What you need is cycle lengths — first day of bleeding to first day of the next — tracked over a year or more, since the criteria compare consecutive cycles.
Two questions follow directly from the staging, and each has its own guide: the perimenopause age range, and how long perimenopause lasts.
When it usually starts, and how long it lasts
Most women begin the menopausal transition between ages 45 and 55 (NIA), and the Office on Women's Health describes perimenopause as usually starting in a woman's mid- to late 40s and lasting about four years on average, with a range of two to eight years (OWH). Cleveland Clinic gives a wider window for onset — as early as the mid-30s, as late as the mid-50s — with the same four-year average (Cleveland Clinic).
Now the average age of menopause, where the sources genuinely disagree. US federal health sources currently give 52: that is the figure on both the NIA page (NIA) and the Office on Women's Health page, which adds a usual range of 45 to 58 (OWH). You will also see 51 cited very widely, including in clinical reference texts. We could not find a current US federal source that gives 51, so we use 52 throughout — but both numbers are genuinely in circulation, and flagging that is more useful to you than quietly picking a side.
One more distinction that gets blurred everywhere: how long the transition lasts and how long symptoms last are different questions with different answers. The transition averages about four years. Symptoms outlast it. In SWAN — the Study of Women's Health Across the Nation — 1,449 women with frequent hot flashes and night sweats had a median total duration of 7.4 years; among the 881 who had an observable final period, symptoms persisted a median of 4.5 years past it. For women whose symptoms started while they were still premenopausal or in early perimenopause, the median total duration was more than 11.8 years (Avis et al., 2015). Onset timing was the single best predictor.
What actually changes
The defining sign is your cycle, not your temperature. Periods may come closer together or further apart, get heavier or lighter, or last longer or shorter than they used to — the NIA puts changes in your period first on its list, as the thing you may notice first (NIA).
Hot flashes and night sweats — vasomotor symptoms — are the best-known feature, and they are genuinely common: they occur in up to 80% of menopausal women, according to the 2023 nonhormone therapy position statement from The Menopause Society (The Menopause Society, 2023). Individual episodes usually run between 30 seconds and 10 minutes, and can arrive several times an hour or twice a week (NIA).
Then there is everything else: disrupted sleep, mood changes, vaginal dryness and urinary changes, and shifts in body composition. Two deserve flagging, because the usual explanation is imprecise. The first is cardiovascular: SWAN Heart data found that although triglycerides rose with age, "only total cholesterol, LDL-C and apoB showed a substantial increase specifically with menopause" — a change tied to the transition itself rather than to simply getting older, while HDL-C rose acutely before menopause and fell after (Woodard et al., 2011). That is the real reason midlife lipid screening matters; our guide to normal cholesterol levels by age covers what those numbers mean. The second is weight, where the standard "hormones make you gain weight" line turns out not to match what the DXA scans actually show. Both get proper treatment elsewhere in this guide: the full symptom picture, with a checklist, and what really happens to weight in perimenopause.
Why it happens
Ovarian function winds down. During the transition, in the NIA's words, "the body's production of estrogen and progesterone, two hormones made by the ovaries, declines greatly" (NIA) — and as it does, the feedback loop between the ovaries and the pituitary gland loses its rhythm. That is why FSH in the early transition is "elevated but variable" rather than simply high, and why the late transition involves "extreme fluctuations in hormonal levels" (Harlow et al., 2012). The swinging is the mechanism, not a side effect of it.
Here is the honest part, and it is more interesting than the confident version. The NIA states plainly that "it isn't clear why hot flashes are so common during the menopausal transition," while noting they are likely related to changing hormone levels (NIA). The working model centres on the brain's control of body temperature, and on a specific population of neurons involved in it.
You can see that model in what the newest drugs were built to do. The FDA describes fezolinetant as a neurokinin 3 receptor antagonist that "works to restore the balance between estrogen hormones and a brain chemical called neurokinin B (NKB) by blocking the activities of the NK3 receptor, which plays a role in the brain's control of body temperature" (FDA). Elinzanetant, approved in October 2025, is a dual NK1 and NK3 receptor antagonist; its FDA label states that blocking NK1 and NK3 signalling "on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can modulate neuronal activity in thermoregulation associated with hot flashes" (FDA label, 2025). Note the word can: a mechanism the labels describe as drug-targetable, not a closed case.
How perimenopause is diagnosed, and why a blood test usually isn't the answer
For most women over 45, this is a clinical diagnosis made from age, symptoms and cycle history — not a lab test. Cleveland Clinic states it directly: "Hormone testing isn't necessary to diagnose perimenopause," and a provider may instead reach the conclusion "based on a physical exam and your symptoms, age and medical history" (Cleveland Clinic).
The reason is the one already established above rather than a general hand-wave about hormones. STRAW+10 characterises early-transition FSH as "elevated but variable," and notes that in the late transition FSH levels are "sometimes elevated into the menopausal range and sometimes within the range characteristic of the earlier reproductive years" (Harlow et al., 2012). A single random draw samples one moment of a process whose defining feature is that it doesn't hold still. That is also the limitation of any test built on a single FSH reading.
Testing does have a role at the edges — the NIA notes a doctor may suggest a blood test to check hormone levels if, for example, periods stopped at an early age (NIA). Testing is the exception here, tied to unusually early onset — not the default route to an answer.
One thing that catches people reading their own after-visit summary: there is no ICD-10-CM code whose descriptor is "perimenopause." The code that gets used is N95.1, "Menopausal and female climacteric states," and it sits under a block header that does say "Menopausal and other perimenopausal disorders" — which is exactly why searching for it returns contradictory answers (AAPC, N95.1). Both threads run further than a definitional page should: whether there is a perimenopause test worth taking, and what the perimenopause ICD-10 code actually covers.
What can be done about it
Hormone therapy remains the most effective treatment for hot flashes and night sweats. The Menopause Society's 2023 statement says so in its own conclusion — that hormone therapy "remains the most effective treatment" and should be considered in menopausal women under 60, within 10 years of their final menstrual period, and without contraindications (The Menopause Society, 2023).
Non-hormonal prescription options exist too, and this is where the guidance has genuinely moved. The 2023 statement gives fezolinetant a Level I recommendation for vasomotor symptoms — but anyone reading that recommendation today needs the update that came after it. On 16 December 2024 the FDA added a Boxed Warning, its most prominent warning, to Veozah (fezolinetant) for rare but serious liver injury, following a post-marketing report of a patient with signs of liver injury after roughly 40 days on the medicine; the FDA now advises liver testing before starting and at intervals during treatment (FDA). Elinzanetant, approved in the US in October 2025 for moderate to severe vasomotor symptoms due to menopause (FDA label, 2025), is newer still — it post-dates the 2023 statement above, and we could not find a current position statement or guideline that covers it.
Then the lifestyle picture, which needs reading precisely. The same 2023 statement lists as not recommended supplements and herbal remedies (Levels I–II) and — at Level II — soy foods and soy extracts, the soy metabolite equol, exercise, yoga, mindfulness-based intervention, relaxation, acupuncture, cooling techniques and avoiding triggers, with dietary modification at Level III (The Menopause Society, 2023). Read that list precisely, because it is a list about one thing only: treating vasomotor symptoms. It is not a finding that exercise, yoga, mindfulness or a good diet are useless in perimenopause. The statement was evaluating one outcome — vasomotor symptoms — and did not assess these interventions for bone density, cardiovascular risk, mood, sleep or muscle mass, which is where the reasons to keep doing them actually come from. And in the very same document, weight loss is affirmatively recommended (Levels II–III) for vasomotor symptoms. Both halves are true at once, and dropping either one produces bad advice.
Three of those threads have their own pages: the full range of treatment options for perimenopause, what to eat during perimenopause, and which perimenopause vitamins and supplements the evidence actually supports. On the herbal side, we have already worked through the strongest available trial evidence for one of the most-asked-about options in our guide to ashwagandha for menopause, including where that evidence stops.
You can still get pregnant during perimenopause
Skipped periods are not contraception. The Office on Women's Health states it without qualification: "You can still get pregnant during perimenopause, the transition to menopause, even if you miss your period for a month or a few months" (OWH).
The practical rule follows from the definition at the top of this page: because menopause cannot be confirmed until a full year has passed without a period, the NIA advises that a woman who does not want to get pregnant should continue using birth control for at least a full 12 months after her last period (NIA). That is the same 12 months that keeps you inside perimenopause under STRAW+10.
When to see a doctor
Irregular periods are expected in perimenopause. These specific patterns are not, and the NIA lists them as reasons to see a doctor (NIA):
- Your periods happen very close together
- You have heavy bleeding
- You have bleeding or spotting after sex or between periods
- Your periods last more than a week
- You start bleeding or spotting again after not having a period for more than a year
One thing that list doesn't cover: symptoms starting before 40. That sits well outside the 45-to-55 window the NIA describes for the transition, and it is worth having properly assessed rather than waited out.
Common questions about perimenopause (FAQ)
What is the first sign of perimenopause? A change in the length of your cycles, not hot flashes. The clinical threshold for the early menopausal transition is a persistent difference of 7 days or more between the lengths of consecutive cycles — for example, a 27-day cycle followed by a 35-day one, with that variability recurring rather than happening once (Harlow et al., 2012).
What is the medical definition of perimenopause? Under the STRAW+10 staging criteria, perimenopause begins at the early menopausal transition — when cycle length becomes persistently variable — and ends 12 months after the final menstrual period (Harlow et al., 2012). It therefore includes the whole first postmenopausal year, not just the years of irregular bleeding.
Can you get pregnant during perimenopause? Yes. The Office on Women's Health states you can still get pregnant during perimenopause even if you miss your period for a month or a few months (OWH), and the National Institute on Aging advises continuing birth control for a full 12 months after your last period if you don't want to conceive (NIA).
Is there a blood test for perimenopause? For most women over 45, no. Cleveland Clinic states that hormone testing isn't necessary to diagnose perimenopause (Cleveland Clinic), because the defining feature of the transition is hormonal variability — STRAW+10 describes early-transition FSH as "elevated but variable," so a single random draw can land anywhere (Harlow et al., 2012).
What age does perimenopause usually start? Most women begin the menopausal transition between ages 45 and 55 (NIA), and the Office on Women's Health describes perimenopause as usually starting in a woman's mid- to late 40s (OWH). Cleveland Clinic notes it can begin as early as the mid-30s or as late as the mid-50s (Cleveland Clinic).
Medical disclaimer: This article is for informational purposes only. Always consult a qualified healthcare provider before making changes to your health routine.
Sources
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause, 2012;19(4) — Peer-reviewed journal article via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3340903/
- National Institute on Aging (NIH). What Is Menopause? — Government health information. https://www.nia.nih.gov/health/menopause/what-menopause
- Office on Women's Health, US Department of Health and Human Services. Menopause basics — Government health information. https://womenshealth.gov/menopause/menopause-basics
- Cleveland Clinic. Perimenopause — Health system disease reference. https://my.clevelandclinic.org/health/diseases/21608-perimenopause
- The North American Menopause Society (The Menopause Society). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 2023;30(6):573–590 — Position statement PDF. https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
- Avis NE, Crawford SL, Greendale G, et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Internal Medicine, 2015 (SWAN) — Peer-reviewed journal article via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4433164/
- Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K. Lipids, Menopause and Early Atherosclerosis in SWAN Heart Women. Menopause, 2011;18(4):376 — Peer-reviewed journal article via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3123389/
- US Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Boxed Warning update posted 16 December 2024 — Drug Safety Communication. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
- US Food and Drug Administration. LYNKUET (elinzanetant) capsules, for oral use — Prescribing information, revised October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf
- AAPC. ICD-10-CM code N95.1 — Menopausal and female climacteric states — Medical coding reference (FY2026 codes). https://www.aapc.com/codes/icd-10-codes/N95.1
All sources accessed 1 August 2026.
Claire Whitfield
A women's health specialist who would rather read the actual staging criteria than a summary of a summary of them.
